Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
927.15
-19.95 (-2.11%) Zydus Lifesciences informs about press release
Date: 30-04-2025 Zydus Lifesciences has informed that it enclosed a copy of press release dated April 30, 2025, titled ‘Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg’.
The above information is a part of company’s filings submitted to BSE.